Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Net Income (2020 - 2025)

Bioventus (BVS) has disclosed Net Income for 5 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income changed N/A year-over-year to $17.3 million, compared with a TTM value of $27.3 million through Dec 2025, changed N/A, and an annual FY2025 reading of $27.3 million, changed N/A over the prior year.
  • Net Income was $17.3 million for Q4 2025 at Bioventus, up from $4.0 million in the prior quarter.
  • Across five years, Net Income topped out at $24.5 million in Q2 2021 and bottomed at -$74.4 million in Q2 2023.
  • Average Net Income over 4 years is -$8.0 million, with a median of -$401000.0 recorded in 2022.
  • The sharpest move saw Net Income surged 133.91% in 2021, then crashed 93484.0% in 2022.
  • Year by year, Net Income stood at -$25000.0 in 2021, then plummeted by 93484.0% to -$23.4 million in 2022, then tumbled by 218.13% to -$74.4 million in 2023, then surged by 123.27% to $17.3 million in 2025.
  • Business Quant data shows Net Income for BVS at $17.3 million in Q4 2025, $4.0 million in Q3 2025, and $9.3 million in Q2 2025.